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Effect of Recombinant Hirudin, a Specific Inhibitor of Thrombin, 
on Endotoxin-induced Intravascular Coagulation and 
Acute Lung Injury in Pigs 1 4 
HANS HOFFMANN, MATTHIAS SIEBECK, MICHAEL SPANNAGL, MARION WEIS, 
REINHARD GEIGER, MARIANNE JOCHUM, and HANS FRITZ 
SUMMARY We hypothesized that thrombin activation may play a prominent role in endotoxin-induced 
secondary organ failure, such as acute lung injury. To test this hypothesis, we administered a thrombin-
specific inhibitor, recombinant hirudin, in endotoxemic pigs. The pigs were anesthetized, mechani-
cally ventilated, and prepared with Swan-Ganz and extravascular lung water (EVLW) catheters. A 
total of 18 randomly selected animals received a pretreatment of 1,000 U/kg of hirudin, followed 
by a continuous infusion over 6 h of 500 U/kg/h given simultaneously with the infusion of 10 ng/kg/h 
of S a l m o n e l l a a b o r t u s e q u i endotoxin. Another 18 animals received a continuous infusion over 
6 h of endotoxin but did not receive hirudin. All animals were fluid resuscitated with 17 ml/kg/h 
of saline for the duration of the experiment. Data are expressed as the mean (95% conf idence inter-
val). Hirudin reduced the endotoxin-induced consumption of plasma fibrinogen from -110 (-138 
to -82) mg/100 ml to - 3 9 (-67 to -12) mg/100 ml (p = 0.0001) and endotoxin-induced increases 
in the soluble fibrin in plasma from 434 (369 to 499) ng/ml to 236 (171 to 300) ng/ml (p = 0.0002). 
These data suggest an effective inhibition of the endotoxin-generated thrombin by hirudin. Further-
more, hirudin signif icantly reduced endotoxin-induced increases in pulmonary vascular resistance 
from 32 (27 to 37) kdyn x s x cm" 5 x kg to 20 (15 to 25) kdyn x s x cm" 5 x kg (p = 0.0015) 
and increases in EVLW from 15.4 (13.2 to 176) ml/kg to 12.2 (10.0 to 14.4) ml/kg (p = 0.0299). The 
administration of hirudin also attenuated the endotoxin-induced loss of protein-rich fluid from the 
vasculature and reduced the plasma PMN elastase concentration in plasma. These results indicate 
that the administration of the thrombin-specific inhibitor hirudin can attenuate endotoxin-induced 
acute lung injury, suggesting an important role of thrombin in endotoxin-induced acute lung injury. 
AM REV RESPIR DIS 1990; 142:782-788 
Introduction 
Septicemiais frequently associated with 
intravascular coagulation and secondary 
organ failure, such as acute lung injury 
(1-3). Infusion of endotoxin (lipopoly-
saccharide [LPS]) into animals has been 
shown to cause an activation of the 
coagulation cascade and to cause acute 
lung injury characterized by pulmonary 
hypertension, pulmonary endothelial in-
jury, increased pulmonary vascular per-
meability, and pulmonary edema (4-8). 
Serine proteases, such as thrombin, plas-
min, or plasma kallikrein, generated dur-
ing activation of the coagulation cascade 
have been shown to activate polymor-
phonuclear leukocytes (PMN) as well as 
to directly increase pulmonary vascular 
permeability (9-12). Thus, these pro-
teases are thought to play a major role 
in the pathophysiology of LPS-induced 
acute lung injury. The response of throm-
bin infusion in animals resembles that 
seen after LPS administration in several 
respects, including pulmonary hyperten-
sion and increased pulmonary vascular 
permeability (10). The direct effects of 
thrombin in vitro include increases in 
endothelial permeability (13), vascular 
smooth muscle contraction (14), activa-
tion of multiple PMN functions (15), and 
thromboxane generation from various 
cells (16-18). In vivo, the thrombin-
induced cleavage of fibrinogen to form 
soluble fibrin, which subsequently poly-
merizes to form fibrin clots, may also be 
a causative factor in LPS-induced acute 
lung injury. Soluble fibrin causes pulmo-
nary hypertension in isolated perfused 
rabbit lungs (19). In addition, thrombin 
may induce the release of tissue Plas-
minogen activator from the endothelial 
cells and thereby activate plasmin (20). 
Fibrin degradation products (FDP) gen-
erated by plasmin are noxious agents in 
the lung and may increase vascular per-
meability (21). Plasmin may also lead to 
complement activation resulting in PMN 
Chemotaxis (22). The sum of these ac-
tions suggests a prominent role of throm-
bin in the pathogenesis of LPS-induced 
acute lung injury. 
In this study, we used the thrombin-
specific inhibitor, recombinant hirudin, 
to investigate the role of thrombin in a 
porcine model of LPS-induced acute 
lung injury. Hirudin, the anticoagulant 
from the medical leech, is a single-chain 
Polypeptide composed of 65 amino acid 
residues with a MT of 7,000 (23). Recent-
ly, recombinant hirudin (r-hirudin) has 
become available (24). r-Hirudin has the 
same inhibitory properties as the natu-
ral protein from the leech (25, 26). 
Hirudin reacts with thrombin in an equi-
molar ratio to form an enzyme-inhibitor 
complex that blocks all the proteolytic 
activity of thrombin (27, 28). In this re-
spect, hirudin functions differently from 
other therapeutic anticoagulants such as 
heparin. Heparin, the antithrombin III 
(AT III) cofactor, accelerates the reaction 
of AT III with thrombin and other clot-
ting factors (29). Thus, the anticoagulant 
effectiveness of heparin depends on the 
concentration of AT III in plasma, which 
is low in cases of septic shock (30, 31). 
The objectives of this study were (1) 
to examine whether hirudin administra-
tion would inhibit the action of throm-
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bin generated during LPS infusion, and 
(2) to determine the effect of hirudin on 
acute lung injury following LPS infusion. 
Methods 
Animals 
Anesthetized weaned miniature pigs of either 
sex (Minipig; Medical Service GmbH, Munich, 
FRG), weighing 18 to 23 kg, were used. The 
animals were fasted overnight, except for un-
limited access to water. Only animals with-
out signs of infection and with a baseline body 
temperature below 38.6° C, Hb above 7.0 g / 
100 ml, WBC 5,000 to 18,000/mm3, and lung 
compliance/kg body weight greater than 1 
were included. All animal procedures were ap-
proved by the Tierschutzreferat, Regierung 
von Oberbayern. 
Anesthesia and Surgical Procedures 
The animals were premedicated with 3 mg/kg 
of azaperone (Stresnil; Janssen, Neuss, FRG) 
and 3.75 mg/kg of metomidate hydrochlo-
ride (Hypnodil; Janssen, Neuss, FRG) inject-
ed intramuscularly. Anesthesia was induced 
with 24 mg/kg of pentobarbital (Narcoren; 
Iffa Merieux, Laupheim, FRG) injected in-
travenously and maintained throughout the 
experiment by a continuous infusion of 0.5 
m g / k g / h of piritramide (Dipidolor; Janssen, 
Neuss, FRG), 0.3 m g / k g / h of pancuronium 
bromide, and 4 m g / k g / h of pentobarbital. 
The animals were orally intubated (Tubus 6.5 
mm, Portex, Hythe, UK) and mechanically 
ventilated (volume cycled) with 40% 0 2 , a re-
spiratory rate of 20 breaths/min, and a tidal 
volume of about 12 ml/kg adjusted to Paco 2 
29 to 33 mm Hg using a Servo Ventilator® 
900C (Siemens-Elema, Solna, Sweden). To 
prevent atelectasis, we hyperinflated the 
animals every 2 min. A large-bore cannula 
and two central venous lines (Cavafix 0.8 x 
1.4 mm x 70 cm; Braun, Melsungen, FRG) 
were placed in the left external jugular vein. 
A 7F Swan-Ganz catheter (7F thermodilution 
catheter; American Edwards Laboratories, 
Anasco, PR) was introduced via the right ex-
ternal jugular vein into a main branch of the 
pulmonary artery. A 5F lung water catheter 
(American Edwards Laboratories, Irvine, CA) 
was inserted through the right femoral artery 
into the abdominal aorta. After preparing the 
animals, we allowed a stabilization period of 
60 min before taking baseline measurements. 
For fluid resuscitation, the animals received 
25 ml/kg of Ringer's lactate during the stabili-
zation period and a continuous infusion of 
17 ml /kg /h during the Observation period 
(this volume included the fluid needed for 
cardiac output (CO) and extravascular lung 
water (EVLW) measurements and for flush-
ing the catheters). If needed, sodium bicar-
bonate (8.4%) was given according to the 
hourly blood gas analysis. 
Experimental Protocol 
After baseline measurements, 36 animals re-
ceived a continuous infusion of 10 u.g/kg/h 
of Salmonella abortus equi endotoxin (LPS, 
batch M6-N1 TEN, 5 mg/ml, kindly provid-
ed by Dr. C. Galanos, Max-Planck Institut 
für Immunologie, Freiburg i.Br., FRG). These 
animals were randomly assigned into two 
groups: 18 animals (with hirudin) received a 
pretreatment of 1,000 U / k g of recombinant 
hirudin (batch: rBH5-7001/2, specific activi-
ty 11,114 U/mg; Plantorgan, Bad Zwischenahn, 
FRG), followed by a continuous infusion over 
6 h of 500 U / k g / h given simultaneously with 
the infusion of LPS. Another 18 animals (w/o 
hirudin) did not receive hirudin but received 
a continuous infusion over 6 h of LPS and 
placebo. All treatments were given as an equal 
volume of 0.3 m l / k g / h . In addition, 6 con-
trol animals received not LPS but saline (n 
= 3) or r-hirudin (n = 3) according to the 
protocol of the corresponding LPS groups. 
Hemodynamic measurements and blood gas 
analysis were performed hourly. EDTA-
anticoagulated or heparinized blood samples 
were drawn every hour and citrated (K10 with 
3.8% citrate) blood samples every 2 h. The 
blood was centrifuged at 1,500 x g for 10 
min and the plasma aliquoted and kept at 
- 80° C until measurement. After the end of 
the 6-h Observation period, the surviving 
animals were sacrificed by the injection of 2.0 
g embutramide + 0.5 g mebezonium-jodine 
+ 0.05 g tetracainhydrochloride (=10 ml of 
T 61; Hoechst Pharmaceuticals, Munich, 
FRG). 
Physiologie and Biochemical Methods 
Mean aortic pressure (Pa), mean pulmonary 
arterial pressure (Ppa), and pulmonary ar-
terial wedge pressure (Ppaw) were continu-
ously monitored using Bentley Trantec Mod-
el 800 transducers, which were referred to the 
level of the atrium. Pressure recordings were 
made on a Sirecust® 404 monitor (Siemens, 
Munich, FRG). Cardiac Output and extravas-
cular lung water were determined in triplicate 
by the single-indicator (10 ml of iced 5% glu-
cose Solution) thermal dilution technique 
using a 9310 lung water Computer (American 
Edwards Laboratories, Santa Ana, CA). The 
thermal Signals from the catheters in the pul-
monary artery and in the aorta were also plot-
ted on a two-channel strip chart recorder (BD 
41; Kipp & Zonen, The Netherlands) for Vi-
sual control. Pulmonary vascular resistance 
(PVR) was calculated as (Ppä - Ppaw)/CO 
x kg body weight) x 79.9. Airway opening 
pressure (Pao) and the tidal volume (VT) were 
measured using a 900C Ventilator. Lung dy-
namic compliance was determined as Cixlyn 
= V T / Pao at the moment of zero airflow 
(end-inspiration). Blood gases were measured 
from heparinized arterial and mixed venous 
blood samples (Model 168 pH/blood gas an-
alyzer; Corning, Medfield, MA). From the 
same samples, we determined 0 2 Saturation 
and Hb using an OSM 2 hemoximeter (Radi-
ometer, Copenhagen, Denmark). Alveolar-
arterial 0 2 difference (AaPo2) was calculated 
from the alveolar gas equation according to 
Thal's formula. Total intravascular protein 
(IVP) was calculated from measurements of 
plasma volume (PV) and total plasma pro-
tein concentration (TP) at baseline and 4 h: 
IVP (g/kg) = PV (ml) x TP (g/ml) 
body weight (kg) 
PV was measured by a dye dilution technique: 
PVX (ml) = V i (ml> x A i 
A x 
PVX = plasma volume at time x 
Vj = volume of injected dye Solution 
Aj = absorbance of injected dye Solution 
A x = absorbance of dye in plasma sample 
at time x 
Vj was determined by weighing the syringe 
before and after the injection of 0.25 ml/kg 
of 1% Evans blue (Sigma) dye Solution intra-
venously. Aj and A x were determined at 620 
nm using a spectrophotometer with appro-
priate corrections for plasma background ab-
sorbance (32). TP was measured with the Stan-
dard biuret method. Leukocyte (WBC) and 
platelet counts were determined on EDTA-
anticoagulated blood samples using a hema-
cytometer (Neubauer Chamber). The activities 
of antithrombin III (AT III), Prothrombin 
(PT), and antiplasmin (AP) in citrated plas-
ma samples were determined using amido-
lytic assays with the specific chromogenic Pep-
tide Substrates S-2238 (H-D-Phe-Pip-Arg-
pNA, Kabi Diagnostica, Stockholm, Sweden), 
Chromozym® TH (Tos-Gly-Pro-Arg-pNA, 
Boehringer, Mannheim, FRG), and S-2251 
(H-D-Val-Leu-Lys-pNA, Kabi Diagnostica, 
Stockholm, Sweden), respectively. The manu-
facturer's Instructions were modified as previ-
ously described (4). Baseline plasma samples 
of all 36 animals were pooled and served as 
reference. AT III, PT, and A P activities are 
given as a percentage of the pool plasma val-
ue. Plasma fibrinogen was determined on 
citrated plasma samples using a functional 
turbidimetric test with batroxobin (Fibrino-
gen Kinetic; Boehringer, Mannheim, FRG). 
Fibrinogen data are presented as a percent-
age of the individual baseline value because 
we observed a considerable variance in base-
line values. Soluble fibrin was measured on 
citrated plasma samples using a functional 
test employing the plasmin-specific chromo-
genic Substrate S-2251 (33). Leukocyte neutral 
Proteinase inhibitor (LNPI) and LNPI-bound 
lysosomal P M N elastase (PMN elastase) in 
plasma were measured on citrated plasma 
samples using enzyme-linked immunosorbent 
assays (ELISA) as recently described (34,35). 
r-Hirudin in plasma was measured on citrat-
ed plasma samples using an ELISA modified 
for porcine plasma (36). 
Statistical Analysis 
We used a factorial analysis of variance to 
analyze the effect of hirudin administration 
on the parameters that we measured (37). We 
employed the paired Student's t test to make 
comparisons within groups. Differences were 
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TABLE 1 
CLOTTING PARAMETERS DURING ENDOTOXIN INFUSION IN PIGS* 
Absence of Hirudin 
(n = 78) 
Presence of Hirudin 
(n = 18) P 
Prothrombin, % Base 106 (100-112) 105 (99-111) 0.8179 
2 h 95 (90-100) 90 (84-95) 0.1655 
Last 67 (61-73) 63 (57-69) 0.6375 
AT III, % Base 99 (93-104) 101 (96-107) 0.4782 
2 h 94 (87-100) 94 (88-101) 0.9245 
Last 81 (75-86) 83 (77-88) 0.5663 
Antiplasmin, % Base 98 (92-104) 96 (90-102) 0.5745 
2 h 91 (85-96) 88 (83-94) 0.5800 
Last 73 (67-79) 71 (64-77) 0.6828 
r-Hirudin, nmol/L Base — — — 
2 h - 72 (62-83) -Last - 104 (89-119) -
Definition of abbreviation: AT III = antithrombin III. 
* Values are mean (95% confidence interval) given as a percentage of the Standard porcine pool 
plasma; p = factorial ANOVA. 
considered significant at p < 0.05, and exact 
p values are given. We detected no significant 
differences in baseline levels of any Parame-
ter that we examined except in baseline WBC 
counts. Data are presented as mean (95% con-
fidence interval) in the absence and presence 
of hirudin. When last measurements are 
presented, the last valid measurements of each 
animal were compared and the time of the 
measurement period was included as a 
covariate. 
Results 
Clotting Parameters 
Infusion of LPS caused a steady decrease 
in Prothrombin and antithrombin III ac-
tivities in plasma. In the absence of 
hirudin, PT feil to approximately 65% 
of baseline by the last measurement; AT 
110-
100-
UJ 
o 
o 90 -z 
er CD 
L_ 80 -
< 
LA
S 70-
Ü_ 
60-
50-
• - • WITH HIRUDIN 
B - G W / O HIRUDIN 
BASE 2 h 4 h LAST 
Fig. 1. Endotoxin-induced decreases in plasma fi-
brinogen in the presence (with hirudin, n = 18) and ab-
sence of hirudin (without hirudin, n = 18) in pigs. Endo-
toxin was given as a continuous intravenous infusion 
of 10 ng/kg/h. Hirudin was administered as an intrave-
nous bolus injection of 1,000 U/kg before endotoxin, 
foliowed by a continuous infusion of 500 U/kg/h simul-
taneously with the endotoxin infusion. Hirudin signifi-
cantly reduced the endotoxin-induced decrease in 
plasma fibrinogen (p = 0.0001). Data expressed as a 
percentage of baseline value (mean [95% confidence 
intervall, factorial ANOVA). 
III decreased to approximately 80% of 
baseline (last measurement). Hirudin had 
no significant effect on the LPS-induced 
changes in PT or AT III activities in plas-
ma (table 1). Plasma fibrinogen was 323 
(295 to 350) mg/100 ml at baseline and 
decreased steadily following LPS infu-
sion. Hirudin reduced the consumption 
of plasma fibrinogen from -110 (-138 
to -82) mg/100 ml in the absence of 
hirudin to - 3 9 ( - 6 7 t o -12) mg/100 ml 
in the presence of hirudin. By the last 
measurement, plasma fibrinogen was 64 
(57 to 71)% of baseline in the absence 
of hirudin and 87 (80 to 94)% of base-
line in the presence of hirudin (p = 
0.0001). The data are shown in figure 1. 
Fibrinogen consumption was paralleled 
by an increase in the soluble fibrin in plas-
ma. In the absence of hirudin, the solu-
ble fibrin in plasma increased from 94 
(65 to 124) ng/ml at baseline to 434 (369 
to 499) ng/ml (last measurement), where-
500-, 
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Fig. 2. Soluble fibrin in plasma during endotoxin infu-
sion in the presence (with hirudin, n = 18) and absence 
of hirudin (without hirudin, n = 18) in pigs. The 
endotoxin-induced increase in the soluble fibrin was 
significantly reduced in the presence of hirudin (p = 
0.0002). Data are mean and 95% confidence interval 
(factorial ANOVA). 
as in the presence of hirudin the increase 
in soluble fibrin was reduced to 236 (171 
to 300) ng/ml (p = 0.0002; figure 2). An-
tiplasmin activities in plasma decreased 
gradually during LPS infusion to approx-
imately 70% of baseline by the last mea-
surement; no significant effect of hirudin 
was detected (table 1). The plasma level 
of hirudin was 72 (62 to 83) nmol/L at 
2 h. A gradual further increase in the 
hirudin concentration in plasma was not-
ed during the continuous hirudin infu-
sion, with values of 104 (89 to 119) 
nmol/L by the last measurement. In con-
trol animals that did not reeeive LPS but 
received saline or hirudin, we detected no 
significant changes in PT, AT III, plas-
ma fibrinogen, soluble fibrin in plasma, 
or AP activities in plasma during the 6-h 
Observation period. 
Physiologie Findings 
The response in mean arterial pressure 
to LPS was similar in the absence or pres-
ence of hirudin. The Pä of both groups 
increased to approximately 9 mm Hg 
above baseline by 30 min and then 
dropped to approximately 30 mm Hg be-
low baseline by 2 h. Thereafter, both 
groups remained hypotensive, showing 
Pa approximately 25 mm Hg below 
baseline by the last measurement (data 
not shown ). Cardiac Output decreased 
to approximately 80% of baseline by 1 h 
and then returned to approximately base-
line level by 2 h in the absence and in 
the presence of hirudin. Thereafter, the 
CO in both groups showed a steady fall 
toward approximately 55% of baseline 
by the last measurement. No significant 
hirudin effect on CO was detected (data 
not shown). PVR was 4.4 (4.2 to 4.7) kdyn 
x s x cm-5 x kg at baseline and 
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Fig. 3. Effect of endotoxin infusion on pulmonary vas-
cular resistance (PVR) in the presence (with hirudin, 
n » 18) and absence of hirudin (without hirudin, n = 
18) in pigs. Hirudin had no effect on the early (< 2 h) 
response but significantly (p = 0.0015) reduced the in-
crease in the later phase. Data are mean and 95% con-
fidence interval (factorial ANOVA). 
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TABLE 2 
LUNG FUNCTION DURING ENDOTOXIN INFUSION IN PIGS* 
Absence of Hirudin Presence of Hirudin 
0.0-
(n = 78) (n = 18) P 
AaPo 2 , mm Hg Base 90 (80-99) 85 (76-94) 0.4870 
2 h 127 (106-148) 116 (95-136) 0.4783 
Last 185 (165-205) 162 (142-181) 0.1027 
CLdyn/kg, ml/mm Hg/kg Base 1.07 (1.03-1.12) 1.12 (1.08-1.17) 0.1332 
2 h 0.75 (0.67-0.84) 0.81 (0.72-0.89) 0.3585 
Last 0.51 (0.45-0.56) 0.58 (0.53-0.64) 0.0863 
Definition of abbreviations: AaPo 2 = aveolar-arterial 0 2 difference; CLdyn/kg = lung dynamic compli-
ance/body weight. 
* Values are mean (95°/o confidence interval); p = factorial ANOVA. 
responded similarly initially to LPS in 
the absence and in the presence of 
hirudin. PVR increased to approximate-
ly three times baseline level by 1 h and 
then decreased to approximately 1.5 x 
baseline at 2 h in the absence and in the 
presence of hirudin. Thereafter, PVR in-
creased again, reaching 32 (27 to 37) kdyn 
x s x cm"5 x kg (last measurement) 
in the absence of hirudin. This increase 
was significantly reduced to 20 (15 to 25) 
kdyn x s x cm"5 x kg in the presence 
of hirudin (p = 0.0015, figure 3). The 
LPS-induced changes in lung dynamic 
compliance (Cixlyn) and in alveolar-
arterial oxygen difference (AaPo2) were 
similar in the absence and in the pres-
ence of hirudin; hirudin had no signifi-
cant effect on either parameter. AaPo2 
increased to approximately two times 
baseline by the last measurement; Cixlyn 
decreased to approximately 50% of base-
line by the last measurement (table 2). 
The extravascular lung water increased 
from 10.1 (9.4 to 10.7) ml/kg at baseline 
to 15.4 (13.2 to 17.6) ml/kg (last measure-
ment) in the absence of hirudin. In the 
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Fig. 4. Extravascular lung water (EVLW) before (base) 
and after (last) endotoxin infusion in the presence (with 
hirudin, n = 18) and absence of hirudin (without 
hirudin, n = 18) in pigs. EVLW was determined by the 
single-indicator thermal dilution technique. The in-
crease in EVLW was significantly smaller in the pres-
ence of hirudin (p = 0.0299). Data are mean and 95% 
confidence interval (factorial ANOVA). 
presence of hirudin, the increase in 
EVLW was significantly reduced to 12.2 
(10.0 to 14.4) ml/kg (p = 0.0299, figure 
4). We calculated the total intravascular 
protein as the product of plasma volume 
times total protein concentration in se-
rum, corrected for body weight. The IVP 
was 2.9 (2.7 to 3.1) g/kg at baseline. 
Hirudin reduced the loss of IVP during 
4 h of LPS infusion from -0.76 (-0.98 
to -0.54) g/kg to -0.49 (-0.72 to 
-0.26) g/kg. This effect was marginally 
significant (p = 0.0448, figure 5). In sa-
line or hirudin control animals, no sig-
nificant changes in Pä, CO, PVR, Cixlyn, 
AaPo2, EVLW, or IVP were noted dur-
ing the Observation period. 
Hematologic Data 
The peripheral leukocyte count (WBC) 
in the absence and in the presence of 
hirudin plummeted within 2 h after the 
Start of the LPS infusion and remained 
low. The leukopenic response was not sig-
nificantly different in the absence or pres-
ence of hirudin. However, since there was 
a significant difference in baseline WBC 
counts in the absence and in the presence 
of hirudin, interpretation of these results 
is limited (table 3). Circulating platelets 
decreased similarly in the absence and 
in the presence of hirudin to approxi-
mately 50% of baseline at the last mea-
surement; hirudin had no significant ef-
fect (table 3). Saline and hirudin control 
-.2-
-A 
< x u 
- . 6 -
- . 8 -
- 1 . 0 J 
WITH HIRUDIN 
W / 0 HIRUDIN 
Fig. 5. Endotoxin-induced changes in total intravas-
cular protein (IVP) in the presence (with hirudin, n = 
18) and absence of hirudin (without hirudin, n = 18) 
in pigs. The IVP was calculated as a product of the plas-
ma volume and the total protein concentration in se-
rum. The differences between measurements at base-
line and 4 h after onset of the endotoxin infusion are 
presented. Hirudin reduced the endotoxin-induced 
loss of IVP (p = 0.0448). Data are mean and 95% con-
fidence interval (factorial ANOVA). 
animals did not show significant changes 
in WBC or platelets. 
PMN Activation 
We measured the concentrations of the 
cytosolic leukocyte neutral Proteinase in-
hibitor (LNPI) and of LNPI-bound 
lysosomal PMN elastase in plasma to as-
sess PMN activation and lysosomal dis-
charge during LPS infusion. The LNPI 
concentration was 150 (138 to 162) ng/ml 
at baseline and increased to approximate-
ly three times baseline level during LPS 
infusion. LNPI by the last measurement 
was 450 (367 to 552) ng/ml in the absence 
of hirudin and 395 (320 to 487) ng/ml 
in the presence of hirudin; this difference 
was not significant (p = 0.0798). PMN 
elastase concentrations in plasma in-
creased from values below the detection 
limit (< 1 ng/ml) at baseline to 37 (27 
to 47) ng/ml in the absence of hirudin, 
whereas in the presence of hirudin this 
increase was significantly reduced to 23 
(13 to 33) ng/ml (p = 0.0137; figure 6). 
In saline and hirudin controls, the LNPI 
concentration in plasma did not change 
and the PMN elastase concentration in 
TABLE 3 
LEUKOCYTE COUNTS (WBC) AND PLATELET COUNTS IN PERIPHERAL 
BLOOD DURING ENDOTOXIN INFUSION IN PIGS* 
Absence of Hirudin 
(n = 18) 
Presence of Hirudin 
(n = 18) P 
WBC, 1,000/mm3 Base 12.1 (10.4-13.7) 9.5 (7.8-11.2) 0.0340 
2 h 3.2 (2.5-4.0) 3.4 (2.6-4.1) 0.7926 
Last 2.0 (1.6-2.5) 2.1 (1.6-2.5) 0.8521 
Platelets, 1,000/mm3 Base 410 (342-478) 380 (314-446) 0.5325 
2 h 265 (213-316) 271 (221-321) 0.8711 
Last 176 (131-221) 203 (159-247) 0.3991 
* Values are mean (95% confidence interval); p = factorial ANOVA. 
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Fig. 6. Leukocyte neutral Proteinase inhibitor (LNPI)-
bound PMN elastase concentrations in porcine plasma 
during endotoxin infusion in the presence (with hirudin, 
n = 18) and absence of hirudin (without hirudin, n = 
18) in pigs. Mean and 95% confidence interval of the 
last valid measurements of each animal are presented. 
At baseline, PMN elastase concentrations in plasma 
were below the detection limit (< 1 ng/ml) in all animals. 
The endotoxin-induced increase in PMN elastase in 
plasma was significantly smaller in the presence of 
hirudin (p = 0.0137; factorial ANOVA). 
plasma was below the detection limit dur-
ing the 6-h Observation period. 
Mortality Rate 
All control animals (n = 6) survived the 
6-h Observation period. Of 36 animals 
given LPS, 5 died between 2 and 4 h af-
ter the Start of the LPS infusion. A total 
of 12 animals died between 4 and 6 h, 
resulting in an overall mortality rate of 
17 of 36 (47%). In the absence of hirudin, 
the mortality rate was 10 of 18 (56%) and 
in the presence of hirudin 7 of 18 (39%), 
respectively. This difference was not sta-
tistically significant (Mantel-Haenszel 
test). 
Discussion 
The results of the present study show that 
hirudin reduces the consumption of plas-
ma fibrinogen and the increase in solu-
ble fibrin in plasma in a porcine model 
of endotoxemia. The administration of 
hirudin also attenuates the increase in 
pulmonary vascular resistance, the in-
crease in extravascular lung water, and 
the loss of protein-rich fluid from the 
vasculature following LPS infusion. 
Furthermore, hirudin reduces the LPS-
induced increase in PMN elastase con-
centration in plasma. 
The LPS-induced consumption of co-
agulation factors in the present study was 
similar to that observed in septic patients 
(2,30). The decrease in plasma Prothrom-
bin and plasma fibrinogen and the in-
crease in soluble fibrin in plasma are evi-
dence of the generation of thrombin. As 
expected, hirudin had no effect on the 
plasma Prothrombin levels but prevent-
ed the consumption of plasma fibrino-
gen and the increase in soluble fibrin in 
plasma; this indicates that hirudin ef fec-
tively inhibits thrombin generated dur-
ing LPS infusion. However, AT III in 
plasma decreased similarly in the absence 
and presence of hirudin. This may not 
be surprising, since the decrease in AT 
III during endotoxemia does not neces-
sarily reflect intravascular coagulation 
(38). The consumption of AT III in en-
dotoxemia may be more the result of un-
specific proteolysis by, for example, PMN 
elastase (4). Furthermore, hirudin did not 
seem to have an inhibitory effect on the 
activation of plasmin since antiplasmin 
activities in plasma were not significant-
ly dif ferent in the absence or presence of 
hirudin. 
It is conceivable that the observed 
hirudin effects result from the Inhibition 
of thrombin by hirudin. Hirudin is a 
highly specific inhibitor of thrombin and 
does not inhibit other serine proteases 
such as trypsin, plasmin, factors IXa, Xa, 
and Xlla, or plasma and tissue kal-
likreins (26, 39). The dose of hirudin we 
administered resulted in plasma levels in 
the ränge of 70 to 100 nmol/L, which 
equal 5 to 9 antithrombin units/ml. Since 
hirudin is a high-affinity inhibitor of 
thrombin that forms enzyme-inhibitor 
complexes in an equimolar ratio (25), this 
dosage ensures sufficient molar inhibi-
tor concentrations if the thrombin con-
centration in plasma during activation 
of the coagulation cascade is assumed 
to be approximately 1 to 2 U/ml (40). 
We determined the total intravascular 
protein as a product of the plasma vol-
ume and the plasma protein concentra-
tion to assess the loss of protein-rich flu-
id from the vasculature during LPS in-
fusion. Hirudin reduced the loss of 
protein-rich fluid by approximately 36%, 
which suggests that thrombin inhibition 
by hirudin may reduce LPS-induced cap-
illary leakage. Furthermore, hirudin at-
tenuated the LPS-induced acute lung in-
jury as evidenced by a smaller increase 
in PVR and in extravascular lung water. 
All animals showed the typical biphasic 
response in PVR to endotoxin (7, 8). 
Hirudin inhibited the increase in the later 
phase, in agreement with previous studies 
using native hirudin from the leech in en-
dotoxemic pigs (5). Hirudin also blunt-
ed the increase in EVLW that occurred 
during LPS infusion. This may be due 
to the reduced pulmonary pressor re-
sponse or to less increase in permeabili-
ty of the lung vasculature to protein; the 
results of the present study do not allow 
us to discriminate between these two pos-
sibilities. Despite reduced EVLW in-
creases in the presence of hirudin, AaPo2 
decreased to the same degree in the ab-
sence and in the presence of hirudin; this 
suggests that pulmonary edema was not 
of major importance in the deterioration 
of pulmonary gas exchange. These find-
ings are in accordance with observations 
in other animal models of LPS-induced 
acute lung injury (7,41) and indicate that 
arterial hypoxemia following LPS infu-
sion is primarily a consequence of venti-
lation/perfusion inequalities. 
It may be exceedingly difficult to de-
termine the separate and specific mech-
anisms of the observed attenuation of 
acute lung injury in the presence of 
hirudin. Less consumption of plasma 
fibrinogen and a smaller increase in the 
soluble fibrin in plasma in the presence 
of hirudin may be one explanation. In 
isolated perfused rabbit lungs, soluble fi-
brin causes vasoconstriction and pulmo-
nary hypertension (19). It is also conceiv-
able, however, that less fibrin generation 
in the presence of hirudin resulted in less 
generation of fibrin degradation prod-
ucts (FDP). FDP released after the ac-
tion of plasmin on fibrin are thought to 
contribute to the development of acute 
lung injury by increasing the permeabil-
ity of the lung vasculature to protein (21, 
42). We have previously shown that the 
infusion of a fibrin-derived peptide into 
pigs causes an increase in EVLW (43). 
However, there may be alternative expla-
nations, other than inhibition of the pro-
teolytic cleavage of fibrinogen by throm-
bin, for the observed hirudin effects. In 
this respect it is notable that in the ab-
sence of fibrinogen in isolated guinea pig 
lungs perfused with Ringer's albumin, 
hirudin also blocks the pulmonary pres-
sure response and pulmonary edema for-
mation after the injection of thrombin 
(44). In this and other models of throm-
bin-induced acute lung injury, as well as 
in models of LPS-induced acute lung in-
jury, the pulmonary hemodynamic re-
sponse has been shown to be mediated 
in part by the generation of cyclo-oxygen-
ase-derived metabolites such as throm-
boxane (8, 44, 45). Thrombin is known 
to directly induce the in vitro generation 
of thromboxane from endothelial cells, 
vascular smooth muscle cells (16,17), and 
PMN leukocytes and lymphocytes (18). 
Hirudin has been shown to abolish the 
thrombin-induced thromboxane gener-
ation from PMN leukocytes and lympho-
cytes in vitro (18). Likewise, hirudin in-
hibited the thrombin-induced contrac-
tion of vascular smooth muscles of 
isolated rabbit aorta and dog coronary 
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arteries (14). Therefore it also seems pos-
sible that hirudin may block the direct 
cellular effects of thrombin that are in-
dependent of the proteolytic cleavage of 
the fibrinogen molecule. 
In animal models of thrombin infu-
sion, PMN leukocytes appeared to be im-
portant in mediating thrombin-induced 
acute lung injury since the response was 
attenuated by PMN depletion (9). We ob-
served a rapid and sustained decrease in 
the circulating leukocyte count follow-
ing endotoxin infusion, but we did not 
detect a significant difference in leukope-
nia in the presence or absence of hirudin. 
One explanation may be that plasmin ac-
tivation occurred similarly in the absence 
and in the presence of hirudin. Plasmin 
causes the cleavage of complement pro-
teins and the formation of the comple-
ment-derived chemotactic peptides, C3a 
and C5a (22,46). On the other hand, the 
thrombin molecule itself is a weak che-
motactic agent and induces PMN aggre-
gation (47); this effect is blocked when 
thrombin is complexed with hirudin (15). 
Although peripheral leukopenia does not 
seem to be affected by hirudin, we pro-
vide evidence that hirudin attenuated the 
lysosomal discharge of PMN leukocytes 
as determined by inhibitor-bound PMN 
elastase concentrations in plasma. Plas-
ma levels of LNPI-bound PMN elastase 
were lower in the presence of hirudin than 
in the absence of hirudin. LNPI, an in-
hibitor of neutral proteinases, was recently 
isoiated and characterized from porcine 
PMN leukocytes (34). The occurrence of 
this inhibitor and of the LNPI-PMN 
elastase complex in plasma has been iden-
tified as a marker of PMN leukocyte ac-
tivation in porcine experimental septice-
mia (35). The data therefore demonstrate 
that hirudin reduces endotoxin-induced 
increases in PMN elastase in plasma, sug-
gesting thrombin activation is an impor-
tant factor in PMN activation after LPS 
infusion. 
In conclusion, our data substantiate 
the role of thrombin in mediating acute 
lung injury following LPS infusion in 
pigs. Possible mechanisms involve the 
generation of soluble fibrin and FDP, a 
direct effect of thrombin, and the acti-
vation of PMN leukocytes. Administra-
tion of hirudin, a highly selective throm-
bin inhibitor, prevented the LPS-induced 
intravascular coagulation and attenuat-
ed the LPS-induced acute lung injury. 
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